Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Mucosal surfaces that line our gastrointestinal tract are continuously exposed to trillions of bacteria that form a symbiotic relationship and impact host health and disease. It is only beginning to be understood that the cross-talk between the host and microbiome involve dynamic changes in commensal bacterial population, secretion, and absorption of metabolites between the host and microbiome. As emerging evidence implicates dysbiosis of gut microbiota in the pathology and progression of various diseases such as inflammatory bowel disease, obesity, and allergy, conventional treatments that either overlook the microbiome in the mechanism of action, or eliminate vast populations of microbes via wide-spectrum antibiotics need to be reconsidered. It is also becoming clear the microbiome can influence the body's response to therapeutic treatments for cancers. As such, targeting the microbiome as treatment has garnered much recent attention and excitement from numerous research labs and biotechnology companies. Treatments range from fecal microbial transplantation to precision-guided molecular approaches. Here, we survey recent progress in the development of innovative therapeutics that target the microbiome to treat disease, and highlight key findings in the interplay between host microbes and therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The fecal or gut microbiome, a diverse community of bacteria, archaea, fungi, protozoa, and viruses, is thought to influence host immunity by modulating multiple immunologic pathways, thus impacting health and disease4–6.”
From Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation (2021) · cites this paper as [5]
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Gut biogeography of the bacterial microbiota
Donaldson, G. P., Lee, S. M., & Mazmanian, S. K. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro3552 · Cited by 2,535
Microbial degradation of complex carbohydrates in the gut
Flint, H. J., Scott, K. P., Duncan, S. H., Louis, P., & Forano, E. (2012) · Gut Microbes · doi:10.4161/gmic.19897 · Cited by 2,331
Bacteria as vitamin suppliers to their host: A gut microbiota perspective
LeBlanc, J. G., Milani, C., de Giori, G. S., Sesma, F., van Sinderen, D., & Ventura, M. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2012.08.005 · Cited by 1,613
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
Research works printed but not linked: 1
- Talbot, A.M. 2017. Vedanta biosciences announces initiation of phase 1a/1b trial for new drug class of rationally-defined bacterial consortia derived from the human microbiome. Business Wire. PureTech Health. Available at https://www.businesswire. com/news/home/20171206006422/en/Vedanta-Biosciences-An nounces-Initiation-Phase-1a1b-Trial (accessed December 07, 2017).
Cited by
The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases
Fogelson, K. A., Dorrestein, P. C., Zarrinpar, A., & Knight, R. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.022 · Cited by 177
Sims, T. T., El Alam, M. B., Karpinets, T. V., Dorta-Estremera, S., Hegde, V. L., Nookala, S., Yoshida-Court, K., Wu, X., Biegert, G. W. G., Delgado Medrano, A. Y., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01741-x · Cited by 135
Gut microbiota restoration through fecal microbiota transplantation: a new atopic dermatitis therapy
Kim, J., Kim, K., & Kim, W. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00627-6 · Cited by 146
The Role of the Microbiome in Food Allergy: A Review
Nance, C. L., Deniskin, R., Diaz, V. C., Paul, M., Anvari, S., & Anagnostou, A. (2020) · Children · doi:10.3390/children7060050 · Cited by 83
“FMT increases microbial diversity, restoring the gut microbiota community structure and diversity to the level of a healthy person [16].”
BackgroundInfluentialGut microbiomes and their metabolites shape human and animal health
Park, W. (2018) · Journal of Microbiology · doi:10.1007/s12275-018-0577-8 · Cited by 61
Metadata
- Authors
- Cho, J. A., & Chinnapen, D. J. F.
- Affiliations
- Chungnam National University (KR)
- Boston Children's Hospital (US)
- Corresponding author
- Chinnapen, Daniel J.F.
- Venue
- Journal of Microbiology
- Publisher
- The Microbiological Society of Korea
- Published
- 2018-02-28
- Volume
- 56
- Issue
- 3
- Pages
- 183-188
- ISSN
- 1225-8873 (ISSN-L)
- 1976-3794
- OpenAlex
- W2794371886
- Cited by
- 19
- References
- 50
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 2
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- The Journal of Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chungnam National University
- National Research Foundation of Korea
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, microbiota-based therapy, dysbiosis, host-microbe interactions, commensal bacteria, metabolite exchange, inflammatory bowel disease, obesity, allergy, cancer immunotherapy, fecal microbiota transplantation, antibiotics
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Anti-Bacterial Agents, Gastrointestinal Diseases, Humans, Hypersensitivity, Neoplasms, Obesity, Symbiosis, Inflammatory Bowel Diseases, Probiotics, Gastrointestinal Tract, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease. https://app.cochat.ai/papers/10.1007/s12275-018-8037-z
- The paper
- Cho, J. A., & Chinnapen, D. J. F. (2018). Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease. Journal of Microbiology. https://doi.org/10.1007/s12275-018-8037-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.